Aspirin Resistance in Systemic Lupus Erythematosus (SLE)

Completed · Phase 1

Conditions studied: Systemic Lupus Erythematosus

In brief

This study examine whether patients with lupus respond to aspirin , and if not, if that is related to inflammation. We examine the ability of aspirin to inhibit the production of thromboxane in patients with lupus and controls and see if aspirin insensitive thromboxane production is inhibited by meloxicam.

Key facts

Study ID

NCT00731302

Run by

Vanderbilt University

People needed

70

Starts

2005-04-01

Expected to finish

2017-04-01

Last updated by the study team

2017-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Written Informed consent.
• Age >18 yrs.
• SLE meeting ACR criteria {Tan, Cohen, et al. 1982 1482 /id} for at least 6 months.(SLE group)
• Stable disease activity as evidenced by no change in immunosuppressive therapy in the past 1 month.
• If female of childbearing potential must use an effective method of birth control
• Exclusion criteria.
• Renal disease (creatinine >1.5 mg/dL, dialysis, 2+ or more proteinuria)
• Previous or current history of peptic ulcer disease or gastrointestinal bleed.
• Previous or current thromboembolic or ischemic cardiovascular event (stroke, myocardial infarction, angina) - can do aspirin part of study.
• Currently taking an anticoagulant or antiplatelet agent (besides aspirin).
• Thrombocytopenia (platelet count <135,000)
• Pregnancy
• Allergy to aspirin, NSAIDs
• NSAIDs in the previous week

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Vanderbilt University Medical School — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.